For each medicine the Formulary provides information on use, dosage, adverse effects, contraindications and warnings, supplemented by guidance on selecting the right medicine for a range of conditions
Брифинг ВОЗ о
1. Распространение курения
2. Смертность, связанная с курением табака
3. Расходы на лечение болезней, связанных с курением табака
4. Воздействие мер, н...аправленных на борьбу с потреблением табака
5. Воздействие налогообложения табачных изделий на здоровье
more
Document d'orientation pour le personnel de santé
The WHO Global Burden of Disease (GBD) study measures the burden of
disease using the disability-adjusted life year metric (DALY). The DALY metric
was developed to assess the burden of disease consistently across diseases,
risk factors and regions. A consistent and comparative description of the ...burden
of diseases and injuries and the risk factors that cause them is important as it
can inform health decision-making and health care planning.
more
Prices people pay for medicines.
Circulating vaccine-derived poliovirus type 2 in Angola
Ebola virus disease in Democratic Republic of the Congo
Dengue fever in Côte d’Ivoire
Humanitarian crisis in north-east Nigeria.
В настоящем докладе освещены текущие и вновь появляющиеся проблемы, связанные с воздействием табака на здоровье детей в Регионе, а также рассмотрены нормативно-пр...авовые механизмы, обязательства и другие инструменты, которые государства-члены должны использовать для защиты детей от табака. Сюда включены и новые подходы, которые можно и нужно применять, для того чтобы Европейский регион стал свободным от табака.
more
As of 15 May 2020, more than 4 million confirmed cases of COVID-19, including more than 285,000 deaths have been reported to WHO. The risk of severe disease and death has been highest in older people and in persons with underlying noncommunicable diseases (NCDs), such as hypertension, cardiac diseas...e, chronic lung disease and cancer.
more
Solidarity” is an international clinical trial to help find an effective treatment for COVID-19, launched by the World Health Organization and partners.
The Solidarity Trial will compare four treatment options against standard of care, to assess their relative effectiveness against COVID-19. By... enrolling patients in multiple countries, the Solidarity Trial aims to rapidly discover whether any of the drugs slow disease progression or improve survival. Other drugs can be added based on emerging evidence.
Until there is sufficient evidence, WHO cautions against physicians and medical associations recommending or administering these unproven treatments to patients with COVID-19 or people self-medicating with them. WHO is concerned by reports of individuals self-medicating with chloroquine and causing themselves serious harm.
more
Several countries have demonstrated that COVID-19 transmission from one person to another can be slowed or stopped. This document has been prepared based on the evidence currently available about Coronavirus disease 2019 (COVID-19) transmission (human-to-human transmission primarily via respiratory... droplets from, or direct contact with, an infected person), and is designed to ensure that the accommodation sector can protect the health of its staff and clients.
more
Ce rapport présente les principaux résultats de l’OMS atteints en 2022 au Niger en étroite collaboration avec le Gouvernement du Niger, les partenaires et d’autres acteurs, dans le cadre de la mise en œuvre du 13e PGT, et dont quatre piliers ont guidé les interventions de l’OMS, à savoir... l’instauration de la couverture sanitaire universelle, l’intervention dans les situations d’urgence sanitaire, la promotion de la santé et du bien-être des populations et le soutien au pays.
more
Cotonou Declaration oBuruli Ulcer
Cotonou, Benin, 30 March 2009
Neglected tropical diseases kill, weaken or incapacitate millions of people every year, causing permanent physical suffering, social stigmatization and reduced productive capacity. Buruli ulcer, one such disease, causes immense suffer...ing and disabilities, especially among children. Delayed schooling and loss of productivity are considerable among the affected populations. These adverse consequences tend to aggravate poverty in affected communities. Globally, the disease has been reported in 30 countries. In WHO’s African Region, Buruli ulcer has been confirmed in 12 countries and is suspected in 10 others.
Significant progress has been made in the past 10 years in knowledge of Buruli
ulcer, investments in related research, control of the disease, and improvement
of tools for case diagnosis and development of treatment protocols. Substantial achievements have been made in diagnosis, treatment, immunology and epidemiology. Despite these achievements, little is known about the exact mode of transmission of the disease, and there is no simple diagnostic test usable in the field.
The use of antibiotics has revolutionized treatment and contributed to reducing the need for surgery by half. However, efforts are still needed to develop simple diagnostic tools usable in the field as well as disability prevention methods. The Global Buruli Ulcer Initiative has adopted the strategy recommended by WHO. The strategy is based on early diagnosis of the disease and the use of antibiotics for treatment upon the onset of the first signs by improving access to screening and case management at the most peripheral level of the health system.
more
La prévalence de la covid -19 chez la femme enceinte et les accouchées semble être faible. Elles étaient asymptomatiques et le pronostic maternel était satisfaisant. Néanmoins, le risque de for.pdf
(Mise à jour décembre 2014)
Des mains propressont des mains sûres. Mes mains sont-elles propres ?
The microbiology laboratory database software.
WHONET is a desktop Windows application for the management and analysis of microbiology laboratory data with a particular focus on antimicrobial resistance surveillance. WHONET, available in 28 languages, supports local, national, regional, and global ...surveillance efforts in over 2,300 hospital, public health, animal health, and food laboratories in over 130 countries worldwide.
more
This module should always be used together with the
mhGAP Intervention Guide for Mental, Neurological
and Substance Use Disorders in Non-specialized Health
Settings (WHO, 2010), which outlines relevant general
principles of care and management of a range of other
mental, neurological and substa...nce use disorders.
(www.who.int/mental_health/publications/mhGAP_
intervention_guide/en/index.html)
In the future, this module may be integrated with other
products in the following ways:
– This module may be integrated – in its full form –
into future iterations of the existing mhGAP Intervention
Guide.
– The module will be integrated –in a simplified structure –
into a new product, the WHO-UNHCR mhGAP Intervention
Guide for Humanitarian Settings (planned for 2014).
more